Jade Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 117.31K shares, a 28.22% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 12.96K shares, a 72.29% decline year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-06-30 was 119.24K shares, a 11.69% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-03-31 was 133.28K shares, a 41.84% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 382.79K shares, a 12.92% increase from fiscal 2023.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 338.99K shares, a 13.48% increase from fiscal 2022.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 298.71K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2024-12-31 | 117.31K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 382.79K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 12.96K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 356.97K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 119.24K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 390.79K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 133.28K shares 10-Q · filed 2024-05-13 | 378.30K shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 91.49K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | 338.99K shares 10-K · filed 2024-03-25 |
| 2023-09-30 | 46.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -95.45M shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 106.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -7.54M shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 93.97K shares 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -95.70M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 298.71K shares 10-K · filed 2023-03-29 |
| 2022-09-30 | 87.96M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2020-09-30 | 1.61K shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |